Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swinging.

Abstract

Intravenous (IV) iron therapy has been a major asset in the management of refractory iron-deficiency anemia in inflammatory bowel disease (IBD) and other diseases. However, the cost-effectiveness of parenteral substitution as the first-line treatment of this condition in IBD has been questioned. A study published by Reinisch et al. in this issue of the journal fails to show non-inferiority of iron isomaltose 1,000, a novel high-dose IV preparation, compared to oral iron sulfate.

• Authors: Gert Van Assche
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 108 Issue 12 Pg. 1889-90 (Dec 2013) ISSN: 1572-0241 [Electronic] United States
• PMID: 24300864 (Publication Type: Editorial, Comment)

Chemical References

• Disaccharides
• Ferric Compounds
• iron isomaltoside 1000
• Iron

Topics

• Anemia, Iron-Deficiency (drug therapy, etiology)
• Disaccharides (therapeutic use)
• Female
• Ferric Compounds (therapeutic use)
• Humans
• Inflammatory Bowel Diseases (complications)
• Iron (therapeutic use)
• Male